A real-life description of polypharmacy in transgender people: results from the ENIGI cohort

View at publisher Summarise with VIRAT
Authors: Jeroen Vervalcke, Stef De Ryck, Arnaud De Clercq, Monica Botte, Lorenzo Marinelli, Gustavo Rodrigues, Alessandra D. Fisher, Martin den Heijer, Guy G. T'Sjoen
Cited by: 0
References: 44

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction Polypharmacy, defined as the concurrent use of five or more pharmacologically active substances, increases the risk of adverse drug events, interactions, and reduced medication adherence. Though traditionally associated with older adults, polypharmacy is also prevalent in younger individuals with chronic or mental health conditions. Transgender and gender diverse individuals may face elevated polypharmacy risk due to higher rates of mental and somatic health conditions, as well as the addition of hormone-related agents with gender-affirming hormone therapy (GAHT).Methodology This prospective cohort study used data from the European Network for the Investigation of Gender Incongruence (ENIGI). Hormone-naïve participants initiating GAHT were followed for a maximum of 36 months. A multivariable logistic regression was performed to identify factors associated with polypharmacy. Temporal trends were analyzed using McNemar’s test.Results Among the 2325 participants in the ENIGI study, 1224 (52.6%) initiated masculinizing gender-affirming hormone therapy (mGAHT), while 1101 (47.4%) began feminizing GAHT (fGAHT). Baseline polypharmacy prevalence was 3.5%, increasing to 10.6% of participants experiencing at least one documented episode of polypharmacy over time. Antidepressants were the most used drug class, not counting GAHT. Dietary supplement use increased significantly. Contraceptive use dropped sharply among individuals on mGAHT. Regression analysis showed higher polypharmacy odds with age, obesity, as well as geographical variation.Conclusion Polypharmacy was uncommon at baseline but increased modestly during the first years of GAHT, particularly among older, obese individuals and those using mGAHT. Antidepressants were the most frequently used drug class. Overall medication use was comparable to general population estimates.

Fields of Study & Subjects

Pharmaceutical Practices and Patient Outcomes LGBTQ Health Identity and Policy Pharmacy and Medical Practices

Publication details

Journal / source
International Journal of Transgender Health
Pages
1–13
Publication date
30 March 2026
Language
EN